Deutsch English Français

Contact

EP3082834

European procedure

Quick help

Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...

News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...

Extract from the Register of European Patents

EP About this file: EP3082834

EP3082834 - STEM CELL DELIVERED ONCOLYTIC HERPES SIMPLEX VIRUS AND METHODS FOR TREATING BRAIN TUMORS [Right-click to bookmark this link]
Status	No opposition filed within time limit Status updated on 15.01.2021 Database last updated on 02.11.2024
Former	The patent has been granted Status updated on 07.02.2020
Former	Grant of patent is intended Status updated on 01.10.2019
Former	Examination is in progress Status updated on 08.06.2018
Most recent event Tooltip	08.07.2022	Lapse of the patent in a contracting state New state(s): AL, MK	published on 10.08.2022 [2022/32]
Applicant(s)	For all designated states The General Hospital Corporation DBA Massachusetts 55 Fruit Street Boston, MA 02114 / US
	[2016/43]
Inventor(s)	01 / SHAH, Khalid 1 Harmony Lane Andover, Massachusetts 01810 / US
	[2016/43]
Representative(s)	Barker Brettell LLP 100 Hagley Road Edgbaston Birmingham B16 8QQ / GB
	[2020/11]
Former [2016/43]	Atkinson, Jennifer Barker Brettell LLP 100 Hagley Road Edgbaston Birmingham B16 8QQ / GB
Application number, filing date	14869630.5	11.12.2014
	[2016/43]
	WO2014US69734
Priority number, date	US201361914481P	11.12.2013 Original published format: US 201361914481 P
	[2016/43]
Filing language	EN
Procedural language	EN
Publication	Type:	A1 Application with search report
	No.:	WO2015089280
	Date:	18.06.2015
	Language:	EN
	[2015/24]
	Type:	A1 Application with search report
	No.:	EP3082834
	Date:	26.10.2016
	Language:	EN
	The application published by WIPO in one of the EPO official languages on 18.06.2015 takes the place of the publication of the European patent application.
	[2016/43]
	Type:	B1 Patent specification
	No.:	EP3082834
	Date:	11.03.2020
	Language:	EN
	[2020/11]
Search report(s)	International search report - published on:	US	18.06.2015
	(Supplementary) European search report - dispatched on:	EP	16.05.2017
Classification	IPC:	A61K48/00, A61K35/35, A61K35/545, C07K14/705, A61K38/17, A61K9/00, A61K35/28, A61K35/30, A61K35/51, A61K35/763, C12N7/00, A61P35/00	[2017/24]
	CPC:	A61K35/763 (EP,US); A61K35/28 (EP,US); A61K35/30 (EP,US); A61K35/35 (EP,US); A61K35/51 (EP,US); A61K35/545 (EP,US); (+) A61K38/177 (EP,US); A61K48/00 (US); A61K9/0019 (US); A61P35/00 (EP); C07K14/705 (EP,US); C12N7/00 (EP,US); C07K14/70575 (EP,US); C12N2710/16132 (EP,US); C12N2710/16632 (US); C12N2710/16671 (US); C12N2830/003 (EP,US) (-)
	Former IPC [2016/43]	A61K35/76
Designated contracting states	AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2016/43]
Extension states	BA	Not yet paid
	ME	Not yet paid
Title	German:	VON STAMMZELLEN ABGEGEBENER ONKOLYTISCHER HERPES-SIMPLEX-VIRUS UND VERFAHREN ZUR BEHANDLUNG VON HIRNTUMOREN	[2016/43]
	English:	STEM CELL DELIVERED ONCOLYTIC HERPES SIMPLEX VIRUS AND METHODS FOR TREATING BRAIN TUMORS	[2016/43]
	French:	VIRUS HERPES SIMPLEX ONCOLYTIQUE DÉLIVRÉ PAR UNE CELLULE SOUCHE ET PROCÉDÉS DE TRAITEMENT DE TUMEURS DU CERVEAU	[2016/43]
Entry into regional phase	04.07.2016	National basic fee paid
	04.07.2016	Search fee paid
	04.07.2016	Designation fee(s) paid
	04.07.2016	Examination fee paid
Examination procedure	04.07.2016	Examination requested [2016/43]
	12.12.2017	Amendment by applicant (claims and/or description)
	11.06.2018	Despatch of a communication from the examining division (Time limit: M06)
	11.12.2018	Reply to a communication from the examining division
	05.04.2019	Despatch of a communication from the examining division (Time limit: M04)
	13.08.2019	Reply to a communication from the examining division
	02.10.2019	Communication of intention to grant the patent
	31.01.2020	Fee for grant paid
	31.01.2020	Fee for publishing/printing paid
	31.01.2020	Receipt of the translation of the claim(s)
Opposition(s)	14.12.2020	No opposition filed within time limit [2021/07]
Fees paid	Renewal fee
	27.12.2016	Renewal fee patent year 03
	27.12.2017	Renewal fee patent year 04
	31.12.2018	Renewal fee patent year 05
	27.12.2019	Renewal fee patent year 06
Opt-out from the exclusive Tooltip competence of the Unified Patent Court	See the Register of the Unified Patent Court for opt-out data
	Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition Tooltip	HU	11.12.2014
	AL	11.03.2020
	AT	11.03.2020
	CY	11.03.2020
	CZ	11.03.2020
	DK	11.03.2020
	EE	11.03.2020
	ES	11.03.2020
	FI	11.03.2020
	HR	11.03.2020
	IT	11.03.2020
	LT	11.03.2020
	LV	11.03.2020
	MC	11.03.2020
	MK	11.03.2020
	MT	11.03.2020
	PL	11.03.2020
	RO	11.03.2020
	RS	11.03.2020
	SE	11.03.2020
	SI	11.03.2020
	SK	11.03.2020
	SM	11.03.2020
	TR	11.03.2020
	BG	11.06.2020
	NO	11.06.2020
	GR	12.06.2020
	IS	11.07.2020
	PT	05.08.2020
	IE	11.12.2020
	LU	11.12.2020
	[2022/31]
Former [2022/27]	HU	11.12.2014
	AT	11.03.2020
	CY	11.03.2020
	CZ	11.03.2020
	DK	11.03.2020
	EE	11.03.2020
	ES	11.03.2020
	FI	11.03.2020
	HR	11.03.2020
	IT	11.03.2020
	LT	11.03.2020
	LV	11.03.2020
	MC	11.03.2020
	MT	11.03.2020
	PL	11.03.2020
	RO	11.03.2020
	RS	11.03.2020
	SE	11.03.2020
	SI	11.03.2020
	SK	11.03.2020
	SM	11.03.2020
	TR	11.03.2020
	BG	11.06.2020
	NO	11.06.2020
	GR	12.06.2020
	IS	11.07.2020
	PT	05.08.2020
	IE	11.12.2020
	LU	11.12.2020
Former [2021/47]	AT	11.03.2020
	CZ	11.03.2020
	DK	11.03.2020
	EE	11.03.2020
	ES	11.03.2020
	FI	11.03.2020
	HR	11.03.2020
	IT	11.03.2020
	LT	11.03.2020
	LV	11.03.2020
	MC	11.03.2020
	PL	11.03.2020
	RO	11.03.2020
	RS	11.03.2020
	SE	11.03.2020
	SI	11.03.2020
	SK	11.03.2020
	SM	11.03.2020
	BG	11.06.2020
	NO	11.06.2020
	GR	12.06.2020
	IS	11.07.2020
	PT	05.08.2020
	IE	11.12.2020
	LU	11.12.2020
Former [2021/46]	AT	11.03.2020
	CZ	11.03.2020
	DK	11.03.2020
	EE	11.03.2020
	ES	11.03.2020
	FI	11.03.2020
	HR	11.03.2020
	IT	11.03.2020
	LT	11.03.2020
	LV	11.03.2020
	MC	11.03.2020
	PL	11.03.2020
	RO	11.03.2020
	RS	11.03.2020
	SE	11.03.2020
	SI	11.03.2020
	SK	11.03.2020
	SM	11.03.2020
	BG	11.06.2020
	NO	11.06.2020
	GR	12.06.2020
	IS	11.07.2020
	PT	05.08.2020
	IE	11.12.2020
Former [2021/40]	AT	11.03.2020
	CZ	11.03.2020
	DK	11.03.2020
	EE	11.03.2020
	ES	11.03.2020
	FI	11.03.2020
	HR	11.03.2020
	IT	11.03.2020
	LT	11.03.2020
	LV	11.03.2020
	MC	11.03.2020
	PL	11.03.2020
	RO	11.03.2020
	RS	11.03.2020
	SE	11.03.2020
	SI	11.03.2020
	SK	11.03.2020
	SM	11.03.2020
	BG	11.06.2020
	NO	11.06.2020
	GR	12.06.2020
	IS	11.07.2020
	PT	05.08.2020
Former [2021/10]	AT	11.03.2020
	CZ	11.03.2020
	DK	11.03.2020
	EE	11.03.2020
	ES	11.03.2020
	FI	11.03.2020
	HR	11.03.2020
	IT	11.03.2020
	LT	11.03.2020
	LV	11.03.2020
	PL	11.03.2020
	RO	11.03.2020
	RS	11.03.2020
	SE	11.03.2020
	SI	11.03.2020
	SK	11.03.2020
	SM	11.03.2020
	BG	11.06.2020
	NO	11.06.2020
	GR	12.06.2020
	IS	11.07.2020
	PT	05.08.2020
Former [2021/09]	AT	11.03.2020
	CZ	11.03.2020
	DK	11.03.2020
	EE	11.03.2020
	ES	11.03.2020
	FI	11.03.2020
	HR	11.03.2020
	IT	11.03.2020
	LT	11.03.2020
	LV	11.03.2020
	RO	11.03.2020
	RS	11.03.2020
	SE	11.03.2020
	SK	11.03.2020
	SM	11.03.2020
	BG	11.06.2020
	NO	11.06.2020
	GR	12.06.2020
	IS	11.07.2020
	PT	05.08.2020
Former [2021/08]	CZ	11.03.2020
	DK	11.03.2020
	EE	11.03.2020
	ES	11.03.2020
	FI	11.03.2020
	HR	11.03.2020
	LT	11.03.2020
	LV	11.03.2020
	RO	11.03.2020
	RS	11.03.2020
	SE	11.03.2020
	SK	11.03.2020
	SM	11.03.2020
	BG	11.06.2020
	NO	11.06.2020
	GR	12.06.2020
	IS	11.07.2020
	PT	05.08.2020
Former [2020/50]	CZ	11.03.2020
	EE	11.03.2020
	FI	11.03.2020
	HR	11.03.2020
	LT	11.03.2020
	LV	11.03.2020
	RO	11.03.2020
	RS	11.03.2020
	SE	11.03.2020
	SK	11.03.2020
	SM	11.03.2020
	BG	11.06.2020
	NO	11.06.2020
	GR	12.06.2020
	IS	11.07.2020
	PT	05.08.2020
Former [2020/49]	CZ	11.03.2020
	FI	11.03.2020
	HR	11.03.2020
	LT	11.03.2020
	LV	11.03.2020
	RO	11.03.2020
	RS	11.03.2020
	SE	11.03.2020
	SK	11.03.2020
	SM	11.03.2020
	BG	11.06.2020
	NO	11.06.2020
	GR	12.06.2020
	IS	11.07.2020
	PT	05.08.2020
Former [2020/48]	FI	11.03.2020
	HR	11.03.2020
	LT	11.03.2020
	LV	11.03.2020
	RO	11.03.2020
	RS	11.03.2020
	SE	11.03.2020
	SM	11.03.2020
	BG	11.06.2020
	NO	11.06.2020
	GR	12.06.2020
	IS	11.07.2020
	PT	05.08.2020
Former [2020/47]	FI	11.03.2020
	HR	11.03.2020
	LT	11.03.2020
	LV	11.03.2020
	RS	11.03.2020
	SE	11.03.2020
	BG	11.06.2020
	NO	11.06.2020
	GR	12.06.2020
	IS	11.07.2020
Former [2020/46]	FI	11.03.2020
	HR	11.03.2020
	LV	11.03.2020
	RS	11.03.2020
	SE	11.03.2020
	BG	11.06.2020
	NO	11.06.2020
	GR	12.06.2020
	IS	11.07.2020
Former [2020/39]	FI	11.03.2020
	HR	11.03.2020
	LV	11.03.2020
	RS	11.03.2020
	SE	11.03.2020
	BG	11.06.2020
	NO	11.06.2020
	GR	12.06.2020
Former [2020/38]	FI	11.03.2020
	HR	11.03.2020
	LV	11.03.2020
	RS	11.03.2020
	SE	11.03.2020
	NO	11.06.2020
	GR	12.06.2020
Former [2020/37]	FI	11.03.2020
	HR	11.03.2020
	LV	11.03.2020
	RS	11.03.2020
	SE	11.03.2020
	NO	11.06.2020
Former [2020/35]	FI	11.03.2020
	NO	11.06.2020
Documents cited:	Search	[XY]US2013189189 (CHANG JONG WOOK [KR], et al) [X] 1-4,11-15 * paragraph [0007] * * paragraph [0041] * * paragraph [0067] * * paragraph [0072] * * paragraph [0103] * * paragraph [0150] * * paragraph [0162] * * paragraph [0218] * * claim - * [Y] 1-15;
		[XY]EP1909849 (BAYLOR COLLEGE MEDICINE [US]) [X] 1,2,5,9,11 * paragraph [0001] * * paragraph [0010] * * paragraph [0016] * * paragraph [0021] * * paragraph [0098] * * paragraph [0108] * [Y] 1-15;
		[XP]WO2014018113 (GEN HOSPITAL CORP [US]) [XP] 1,3,5-9 * paragraph [0006] * * paragraph [0032] - paragraph [0033] * * paragraph [0116] - paragraph [0117] * * claim - *;
		[YD]WO2012106281 (GEN HOSPITAL CORP [US], et al) [YD] 1-15 * paragraph [0088] - paragraph [0091] * * paragraph [0261] - paragraph [0262] * * claim - *
		[XY] - Tyrel Smith ET AL, "Human Bone Marrow-Derived Mesenchymal Stem Cells for Intranasal Delivery of Oncolytic Herpes Simplex Virus Type I to Human Gliomas", Molecular Therapy, (20130601), pages s246 - s247, URL: http://www.cell.com/molecular-therapy-family/molecular-therapy/pdf/S1525-0016(16)34981-4.pdf, (20170504), XP055369722 [X] 1-4,11-13,15 * the whole document * [Y] 1-15
		[XY] - VOSS ET AL, "Delivery of Oncolytic Herpes Simplex Virus to Infiltrative Brain Tumor Sites Via Neuronal Stem Cells", MOLECULAR THERAPY, ACADEMIC PRESS, US, (20060101), vol. 13, doi:10.1016/J.YMTHE.2005.10.013, ISSN 1525-0016, page S411, XP005676178 [X] 1-3,11-13,15 * the whole document * [Y] 1-15 DOI: http://dx.doi.org/10.1016/j.ymthe.2005.10.013
		[X] - HIROAKI WAKIMOTO ET AL, "Human glioblastoma-derived cancer stem cells: establishment of invasive glioma models and treatment with oncolytic herpes simplex virus vectors", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 69, no. 8, doi:10.1158/0008-5472.CAN-08-3886, ISSN 0008-5472, (20090415), pages 3472 - 3481, (20090407), XP008141764 [X] 1-3,7 * abstract * * page 3473, column l, paragraph Materials and methods - column r, paragraph first * * page 3475, column r, paragraphs oHSVs infect, replicate, and spread in GBM - page 3476, column r, line 4 * DOI: http://dx.doi.org/10.1158/0008-5472.CAN-08-3886
		[XY] - KAORU TAMURA ET AL, "Multimechanistic Tumor Targeted Oncolytic Virus Overcomes Resistance in Brain Tumors", MOLECULAR THERAPY, US, (20130101), vol. 21, no. 1, doi:10.1038/mt.2012.175, ISSN 1525-0016, pages 68 - 77, XP055369717 [X] 1,6-9 * abstract * * page 75, column r, line 4 - line 13 * * page 75, column r, line 35 - page 76, column l, line 21 * [Y] 1-15 DOI: http://dx.doi.org/10.1038/mt.2012.175
		[Y] - JIANG Y ET AL, "A new approach with less damage: intranasal delivery of tetracycline-inducible replication-defective herpes simplex virus type-1 vector to brain", NEUROSCIENCE, NEW YORK, NY, US, vol. 201, doi:10.1016/J.NEUROSCIENCE.2011.10.043, ISSN 0306-4522, (20111022), pages 96 - 104, (20111110), XP028437742 [Y] 1-15 * abstract * * page 97, column l, paragraph Animals - column r, paragraph Vector delivery * * page 100, column l, paragraph Tetracycline * * page 103, column l, paragraph Conclusion * DOI: http://dx.doi.org/10.1016/j.neuroscience.2011.10.043
	International search	[X]US2005214266 (MORRIS DONALD [CA], et al);
		[A]US8222036 (THOMPSON BRADLEY G [CA], et al);
		[A]US2010272686 (KAUR BALVEEN [US], et al);
		[A]US7790451 (YAZAKI TAKAHITO [JP], et al);
		[A]US2011177032 (MARTUZA ROBERT [US], et al)
	Examination	- Prakash Rath ET AL, "Stem Cells as Vectors to Deliver HSV/tk Gene Therapy for Malignant Gliomas", Current Stem Cell Research & Therapy, AE, (20090101), vol. 4, no. 1, doi:10.2174/157488809787169138, ISSN 1574-888X, pages 44 - 49, XP055481262 DOI: http://dx.doi.org/10.2174/157488809787169138
		- Prakash Rath ET AL, "Stem Cells as Vectors to Deliver HSV/tk Gene Therapy for Malignant Gliomas", Current Stem Cell Research & Therapy, AE, (20090101), vol. 4, no. 1, doi:10.2174/157488809787169138, ISSN 1574-888X, pages 44 - 49, XP055481273 DOI: http://dx.doi.org/10.2174/157488809787169138
		- James J. Cody ET AL, "Preclinical Evaluation of Oncolytic [Delta] [gamma] 1 34.5 Herpes Simplex Virus Expressing Interleukin-12 for Therapy of Breast Cancer Brain Metastases", International Journal of Breast Cancer, (20120101), vol. 2012, doi:10.1155/2012/628697, ISSN 2090-3170, pages 1 - 12, XP055481292 DOI: http://dx.doi.org/10.1155/2012/628697
		- James J. Cody ET AL, "Preclinical Evaluation of Oncolytic [Delta] [gamma] 1 34.5 Herpes Simplex Virus Expressing Interleukin-12 for Therapy of Breast Cancer Brain Metastases", International Journal of Breast Cancer, (20120101), vol. 2012, doi:10.1155/2012/628697, ISSN 2090-3170, pages 1 - 12, XP055481295 DOI: http://dx.doi.org/10.1155/2012/628697
	by applicant	US7063835
		US8236941
		WO2012106281
		US2010323399
		US4518584
		US4737462
		US2002128438
		US5037743
		US5143830
		US2011014656
		US2010305002
		US2010240097
		WO9410308
		US5716805
		US5358866
		US5688773
		US5288641
		- COUKOS GMAKRIGIANNAKIS AKANG EH et al., "Use of carrier cells to deliver a replication-selective herpes simplex virus-1 mutant for the intraperitoneal therapy of epithelial ovarian cancer", Clin Cancer Res, (19990000), vol. 5, no. 6, pages 1523 - 248, XP000979399
		- COUKOS et al., Gene Ther. Mol. Biol., (19980000), vol. 3, pages 79 - 89
		- VARGHESERABKIN, Cancer Gene Therapy, (20020000), vol. 9, pages 967 - 978
		- TODO et al., Proc. Natl. Acad. Sci. USA, (20010000), vol. 98, pages 6396 - 6401
		- MIYATAKE et al., J. Virol., (19970000), vol. 71, pages 5124 - 5132
		- J. M. A. KUIJLEN et al., Neuropathology and Applied Neurobiology, (20100000), vol. 36, no. 3, pages 168 - 182
		- WALDER et al., Gene, (19860000), vol. 42, page 133
		- BAUER et al., Gene, (19850000), vol. 37, page 73
		- CRAIK, BioTechniques, (19850100), pages 12 - 19
		- SMITH et al., Cell, (19930000), vol. 75, page 1169
		- SMITH et al., Cell, (19940000), vol. 76, page 959
		- GOODWIN et al., Eur. J. Immunol., (19930000), vol. 23, page 2631
		- MCLACHLANSTEWART, J. Mol. Biol., (19750000), vol. 98, pages 293 - 75
		- ASHKENAZI A. et al., J Clin Oncol, (20080000), vol. 26, pages 3621 - 30
		- KELLEY SK et al., J Pharmacol Exp Ther, (20010000), vol. 299, pages 31 - 8
		- BREMER E. et al., J Mol Med, (20080000), vol. 86, pages 909 - 24
		- FUKUHARA, H. et al., "Triple gene-deleted oncolytic herpes simplex virus vector double-armed with interleukin 18 and soluble B7-1 constructed by bacterial artificial chromosome-mediated system", Cancer Res, (20050000), vol. 65, no. 23, doi:doi:10.1158/0008-5472.CAN-05-2534, pages 10663 - 88, XP002454933 DOI: http://dx.doi.org/10.1158/0008-5472.CAN-05-2534
		- BREMER E et al., J Biol Chem, (20050000), vol. 280, pages 10025 - 33
		- STIEGLMAIER J et al., Cancer Immunol Immunother, (20080000), vol. 57, pages 233 - 46
		- SHAH et al., Cancer Research, (20040000), vol. 64, pages 3236 - 3242
		- SHAH et al., Mol Ther., (20050600), vol. 11, no. 6, pages 926 - 3 1
		- "GenBank", Database accession no. P49772
		- CHOO et al., BMC Bio informatics, (20050000), vol. 6, page 249
		- SPRENGER et al., Nuc Acids Res, (20080000), vol. 36, page D230D233
		- LADUNGA, Curr Opin Biotech, (20000000), vol. 1, pages 13 - 18
		- STERN et al., Trends in Cell & Molecular Biology, (20070000), vol. 2, pages 1 - 17
		- BARASH et al., Biochem Biophys Res Comm, (20020000), vol. 294, pages 835 - 842
		- KRYSTEK et al., Int. J. Peptide Res., (19910000), vol. 38, page 229
		- LANDSCHULZ et al., Science, (19880000), vol. 240, page 1759
		- LANDSCHULZ et al., Science, (19890000), vol. 243, page 1681
		- BUCKLANDWILD, Nature, (19890000), vol. 338, page 547
		- BRITTON, Nature, (19910000), vol. 353, page 394
		- DELWARTMOSIALOS, AIDS Research and Human Retrovirtises, (19900000), vol. 6, page 703
		- SPRUCE et al., Proc. Natl. Acad. Sci. U.S.A., (19910000), vol. 88, page 3523
		- RABINDRAN et al., Science, (19930000), vol. 259, page 230
		- HOPPE et al., FEBS Letters, (19940000), vol. 344, page 191
		- FANSLOW et al., Semin. Immunol., (19940000), vol. 6, pages 267 - 278
		- MARTUZA et al., Science, (19910000), vol. 252, page 854
		- "UniProtKB", Database accession no. Q9NR283
		- KHALID SHAH, "Encapsulated Stem Cells for Cancer Therapy", Biomatter., (20130101), vol. 3, no. 1, page e24278
		- BURDICK et al., Adv Mater., (20110000), pages 23H41 - 56
		- ALLISON et al., "Hyaluronan: a powerful tissue engineering tool", Tissue Eng., (20060000), vol. 12, pages 2131 - 40, XP055082448
		- PRESTWICH, J Control Release, (20110000), vol. 155, pages 193 - 9
		- PRESTWICH, J Cell Biochem., (20070000), vol. 101, pages 1370 - 83
		- PRESTWICH, Acc Chem Res., (20080000), vol. 41, pages 139 - 48
		- SHU et al., Biomaterials, (20030000), vol. 24, pages 3825 - 34
		- SHU et al., Biomacromolecules, (20020000), vol. 3, pages 1304 - 11
	- VANDERHOOFT et al., Biomacromolecules, (20070000), vol. 8, pages 2883 - 9
	- VANDERHOOFT et al., Macromol Biosci., (20090000), vol. 9, pages 20 - 8
	- PAN et al., J Neurosci Res., (20090000), vol. 87, pages 3207 - 20
	- SAYYAR et al., J Tissue Eng., (20120000), vol. 3, page 2041731412462018
	- PARK et al., Gene Ther., (20020000), vol. 9, pages 613 - 24
	- TENG et al., Proc Natl Acad Sci USA., (20020000), vol. 99, pages 3024 - 9
	- WEN, P.Y.S. KESARI, "Malignant gliomas in adults", N Engl J Med, (20080000), vol. 359, no. 5, pages 492 - 507
	- JOHNSON, D.R.S.M. CHANG, "Recent medical management of glioblastoma", Adv Exp Med Biol, (20120000), vol. 746, pages 26 - 40
	- JOHANNESSEN, T.C.R. BJERKVIG, "Molecular mechanisms of temozolomide resistance in glioblastoma multiforme", Expert Rev Anticancer Ther, (20120000), vol. 12, no. 5, pages 635 - 42
	- BARR, J.G.P.L. GRUNDY, "The effects of the NICE Technology Appraisal 121 (Gliadel and temozolomide) on survival in high-grade glioma", Br J Neurosurg, (20120000), vol. 26, no. 6, pages 818 - 22
	- AGHI, M.R.L. MARTUZA, "Oncolytic viral therapies - the clinical experience", Oncogene, (20050000), vol. 24, no. 52, doi:doi:10.1038/sj.onc.1209037, pages 7802 - 7816, XP055348661 DOI: http://dx.doi.org/10.1038/sj.onc.1209037
	- LIU, T.C.E. GALANISD. KIRN, "Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress", Nat Clin Pract Oncol, (20070000), vol. 4, no. 2, doi:doi:10.1038/ncponc0736, pages 101 - 17, XP009100877 DOI: http://dx.doi.org/10.1038/ncponc0736
	- MARKERT, J.M. et al., "Conditionally replicating herpes simplex virus mutant, G207for the treatment of malignant glioma: results of a phase I trial", Gene Ther, (20000000), vol. 7, no. 10, pages 867 - 74
	- WAKIMOTO HKESARI SFARRELL CJ et al., "Human glioblastoma-derived cancer stem cells: establishment of invasive glioma models and treatment with oncolytic herpes simplex virus vectors", Cancer Res, (20090000), vol. 69, no. 8, doi:doi:10.1158/0008-5472.CAN-08-3886, pages 3472 - 81, XP008141764 DOI: http://dx.doi.org/10.1158/0008-5472.CAN-08-3886
	- VARGHESE, S.S.D. RABKIN, "Oncolytic herpes simplex virus vectors for cancer virotherapy", Cancer Gene Ther, (20020000), vol. 9, no. 12, doi:doi:10.1038/sj.cgt.7700537, pages 967 - 78, XP002313119 DOI: http://dx.doi.org/10.1038/sj.cgt.7700537
	- HOFFMANN, D.O. WILDNER, "Comparison of herpes simplex virus- and conditionally replicative adenovirus-based vectors for glioblastoma treatment", Cancer Gene Ther, (20070000), vol. 14, no. 7, doi:doi:10.1038/sj.cgt.7701055, pages 627 - 39, XP003021233 DOI: http://dx.doi.org/10.1038/sj.cgt.7701055
	- TODO, T., "Armed'' oncolytic herpes simplex viruses for brain tumor therapy", Cell Adh Migr, (20080000), vol. 2, no. 3, doi:doi:10.4161/cam.2.3.6353, pages 208 - 13, XP055594753 DOI: http://dx.doi.org/10.4161/cam.2.3.6353
	- MARKERT JMLIECHTY PGWANG W et al., "Phase Ib trial of mutant herpes simplex virus G207 inoculated pre-and post-tumor resection for recurrent GBM", Mol Ther, (20090000), vol. 17, no. 1, pages 199 - 207
	- HARROW SPAPANASTASSIOU VHARLAND J et al., "HSV1716 injection into the brain adjacent to tumour following surgical resection of high-grade glioma: safety data and long-term survival", Gene Ther, (20040000), vol. 11, no. 22, doi:doi:10.1038/sj.gt.3302289, pages 1648 - 5 8, XP055022166 DOI: http://dx.doi.org/10.1038/sj.gt.3302289
	- RAMPLING RCRUICKSHANK GPAPANASTASSIOU V et al., "Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma", Gene Ther, (20000000), vol. 7, no. 10, doi:doi:10.1038/sj.gt.3301184, pages 859 - 66, XP055557968 DOI: http://dx.doi.org/10.1038/sj.gt.3301184
	- PAPANASTASSIOU, V. et al., "The potential for efficacy of the modified (ICP 34.5(-)) herpes simplex virus HSV1716 following intratumoural injection into human malignant glioma: a proof ofprinciple study", Gene Ther, (20020000), vol. 9, no. 6, pages 398 - 406
	- GARCIA-CASTRO JALEMANY RCASCALLO M et al., "Treatment of metastatic neuroblastoma with systemic oncolytic virotherapy delivered by autologous mesenchymal stem cells: an exploratory study", Cancer Gene Ther, (20100000), vol. 17, no. 7, doi:doi:10.1038/cgt.2010.4, pages 476 - 83, XP055582249 DOI: http://dx.doi.org/10.1038/cgt.2010.4
	- KOMAROVA SKAWAKAMI YSTOFF-KHALILI MA et al., "Mesenchymal progenitor cells as cellular vehicles for delivery of oncolytic adenoviruses", Mol Cancer Ther, (20060000), vol. 5, no. 3, pages 755 - 66, XP002590129
	- RAYKOV ZBALBONI GAPRAHAMIAN M et al., "Carrier cell-mediated delivery of oncolytic parvoviruses for targeting metastases", Int J Cancer, (20040000), vol. 109, no. 5, doi:doi:10.1002/ijc.20013, pages 742 - 9, XP002554386 DOI: http://dx.doi.org/10.1002/ijc.20013
	- JEVREMOVIC DGULATI RHENNIG I et al., "Use of blood outgrowth endothelial cells as virus-producing vectors for gene delivery to tumors", Am J Physiol Heart Circ Physiol, (20040000), vol. 287, no. 2, doi:doi:10.1152/ajpheart.00064.2004, pages H494 - 500, XP003018195 DOI: http://dx.doi.org/10.1152/ajpheart.00064.2004
	- CRITTENDEN MGOUGH MCHESTER J et al., "Pharmacologically regulated production of targeted retrovirus from T cells for systemic antitumor gene therapy", Cancer Res, (20030000), vol. 63, no. 12, pages 3173 - 80, XP003018194
	- TYLER MAULASOV IVSONABEND AM et al., "Neural stem cells target intracranial glioma to deliver an oncolytic adenovirus in vivo", Gene Ther, (20090000), vol. 16, no. 2, doi:doi:10.1038/gt.2008.165, pages 262 - 78, XP055176021 DOI: http://dx.doi.org/10.1038/gt.2008.165
	- YONG RLSHINOJIMA NFUEYO J et al., "Human bone marrow-derived mesenchymal stem cells for intravascular delivery of oncolytic adenovirus Delta24-RGD to human gliomas", Cancer Res, (20090000), vol. 69, no. 23, pages 8932 - 40
	- KAUER TMFIGUEIREDO JLHINGTGEN S et al., "Encapsulated therapeutic stem cells implanted in the tumor resection cavity induce cell death in gliomas", Nat Neurosci, (20120000), vol. 15, no. 2, doi:doi:10.1038/nn.3019, pages 197 - 204, XP055204981 DOI: http://dx.doi.org/10.1038/nn.3019
	- ZEMP, F.J. et al., "Oncolytic viruses as experimental treatments for malignant gliomas: using a scourge to treat a devil", Cytokine Growth Factor Rev, (20100000), vol. 21, no. 2-3, doi:doi:10.1016/j.cytogfr.2010.04.001, pages 103 - 17, XP027066630 DOI: http://dx.doi.org/10.1016/j.cytogfr.2010.04.001
	- WOLLMANN, G.K. OZDUMANA.N. VAN DEN POL, "Oncolytic virus therapy for glioblastoma multiforme: concepts and candidates", Cancer J, (20120000), vol. 18, no. 1, pages 69 - 81
	- PEREBOEVA LKOMAROVA SMIKHEEVA G et al., "Approaches to utilize mesenchymal progenitor cells as cellular vehicles", Stem Cells, (20030000), vol. 21, no. 4, doi:doi:10.1634/stemcells.21-4-389, pages 389 - 404, XP055559170 DOI: http://dx.doi.org/10.1634/stemcells.21-4-389
	- SASPORTAS, L.S. et al., "Assessment of therapeutic efficacy and fate of engineered human mesenchymal stem cells for cancer therapy", Proc Natl Acad Sci USA, (20090000), vol. 106, no. 12, doi:doi:10.1073/PNAS.0806647106, pages 4822 - 7, XP002785176 DOI: http://dx.doi.org/10.1073/PNAS.0806647106
	- KONG, D.S. et al., "Preservation of quality of life by preradiotherapy stereotactic radiosurgery for unresectable glioblastoma multiforme", J Neurosurg, (20060000), no. 105, pages 139 - 43
	- LESIMPLE, T. et al., "Topotecan in combination with radiotherapy in unresectable glioblastoma: a phase 2 study", J Neurooncol, (20090000), vol. 93, no. 2, pages 253 - 60, XP019685321
	- YAO, F. et al., "Highly efficient regulation of gene expression by tetracycline in a replication-defective herpes simplex viral vector", Mol Ther, (20060000), vol. 13, no. 6, doi:doi:10.1016/j.ymthe.2006.01.009, pages 1133 - 41, XP005469387 DOI: http://dx.doi.org/10.1016/j.ymthe.2006.01.009
	- YAO, F. et al., "Development of a regulatable oncolytic herpes simplex virus type 1 recombinant virus for tumor therapy", J Virol, (20100000), vol. 84, no. 16, pages 8163 - 71
	- CHATURVEDI, A.K. et al., "Validation of the tetracycline regulatable gene expression system for the study of the pathogenesis of infectious disease", PLoS One, (20110000), vol. 6, no. 5, page e20449
	- ZHANG, W. et al., "Bevacizumab with angiostatin-armed oHSV increases antiangiogenesis and decreases bevacizumab-induced invasion in U87 glioma", Mol Ther, (20120000), vol. 20, no. 1, doi:doi:10.1038/mt.2011.187, pages 37 - 45, XP008156750 DOI: http://dx.doi.org/10.1038/mt.2011.187
	- CASTELO-BRANCO PPASSER BJBUHRMAN JS et al., "Oncolytic herpes simplex virus armed with xenogeneic homologue of prostatic acid phosphatase enhances antitumor efficacy in prostate cancer", Gene Ther, (20100000), vol. 17, no. 6, pages 805 - 10
	- LI JZENG WHUANG Y et al., "Treatment of breast cancer stem cells with oncolytic herpes simplex virus", Cancer Gene Ther, (20120000), vol. 19, no. 10, pages 707 - 14
	- SHAH KHINGTGEN SKASMIEH R et al., "Bimodal viral vectors and in vivo imaging reveal the fate of human neural stem cells in experimental glioma model", J Neurosci, (20080000), vol. 28, no. 17, pages 4406 - 13
	- KURODA, T. et al., "Flip-Flop HSV-BAC: bacterial artificial chromosome based system for rapid generation of recombinant herpes simplex virus vectors using two independent site-specific recombinases", BMC Biotechnol, (20060000), vol. 6, doi:doi:10.1186/1472-6750-6-40, page 40, XP021023576 DOI: http://dx.doi.org/10.1186/1472-6750-6-40
	- SAEKI, Y. et al., "Herpes simplex virus type 1 DNA amplified as bacterial artificial chromosome in Escherichia coli: rescue of replication-competent virus progeny and packaging of amplicon vectors", Hum Gene Ther, (19980000), vol. 9, no. 18, pages 2787 - 94
	- YAMAMOTO, S. et al., "Imaging immediate-early and strict-late promoter activity during oncolytic herpes simplex virus type 1 infection and replication in tumors.", Gene Ther, (20060000), vol. 13, no. 24, doi:doi:10.1038/sj.gt.3302831, pages 1731 - 6, XP002462923 DOI: http://dx.doi.org/10.1038/sj.gt.3302831
	- CORSTEN, M.F. et al., "MicroRNA-21 knockdown disrupts glioma growth in vivo and displays synergistic cytotoxicity with neural precursor cell delivered S- TRAIL in human gliomas.", Cancer Res, (20070000), vol. 67, no. 19, pages 8994 - 9000
	- KOCK NKASMIEH RWEISSLEDER R et al., "Tumor therapy mediated by lentiviral expression of shBcl-2 and S-TRAIL", Neoplasia, (20070000), vol. 9, no. 5, doi:doi:10.1593/neo.07223, pages 435 - 42, XP002629225 DOI: http://dx.doi.org/10.1593/neo.07223
	- HINGTGEN SFIGUEIREDO JLFARRAR C et al., "Real-time multi-modality imaging of glioblastoma tumor resection and recurrence", J Neurooncol, (20130000), vol. 111, no. 2, doi:doi:10.1007/s11060-012-1008-z, pages 153 - 61, XP035149907 DOI: http://dx.doi.org/10.1007/s11060-012-1008-z
	- MARKERT JMMEDLOCK MDRABKIN SD et al., "Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial", Gene Ther, (20000000), vol. 7, no. 10, pages 867 - 74
	- PAPANASTASSIOU VRAMPLING RFRASER M et al., "The potential for efficacy of the modified (ICP 34.5(-)) herpes simplex virus HSV1716 following intratumoural injection into human malignant glioma: a proof of principle study", Gene Ther, (20020000), vol. 9, no. 6, pages 398 - 406
	- MOHYELDIN ACHIOCCA EA, "Gene and viral therapy for glioblastoma: a review of clinical trials and future directions", Cancer J, (20120000), vol. 18, no. 1, pages 82 - 8
	- KAUR BCHIOCCA EACRIPE TP, "Oncolytic HSV-1 virotherapy: clinical experience and opportunities for progress", Curr Pharm Biotechnol, (20120000), vol. 13, no. 9, pages 1842 - 51
	- SASPORTAS LSKASMIEH RWAKIMOTO H et al., "Assessment of therapeutic efficacy and fate of engineered human mesenchymal stem cells for cancer therapy", Proc Natl Acad Sci U S A, (20090000), vol. 106, no. 12, doi:doi:10.1073/PNAS.0806647106, pages 4822 - 7, XP002785176 DOI: http://dx.doi.org/10.1073/PNAS.0806647106
	- MARTINEZ-QUINTANILLA JBHERE DHEIDARI P et al., "Therapeutic efficacy and fate of bimodal engineered stem cells in malignant brain tumors", Stem Cells, (20130000), vol. 31, no. 8, doi:doi:10.1002/stem.1355, pages 1706 - 14, XP055459331 DOI: http://dx.doi.org/10.1002/stem.1355
	- CHEEMA TAWAKIMOTO HFECCI PE et al., "Multifaceted oncolytic virus therapy for glioblastoma in an immunocompetent cancer stem cell model", Proc Natl Acad Sci U S A, (20130000), vol. 110, no. 29, pages 12006 - 11
	- SHAH KBUREAU EKIM DE et al., "Glioma therapy and real-time imaging of neural precursor cell migration and tumor regression", Ann Neurol, (20050000), vol. 57, no. 1, pages 34 - 41
	- CORSTEN MFSHAH K, "Therapeutic stem-cells for cancer treatment: hopes and hurdles in tactical warfare", Lancet Oncol, (20080000), vol. 9, no. 4, doi:doi:10.1016/S1470-2045(08)70099-8, pages 376 - 84, XP022593857 DOI: http://dx.doi.org/10.1016/S1470-2045(08)70099-8
	- LEE JKOTLIAROVA SKOTLIAROV Y et al., "Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines", Cancer Cell, (20060000), vol. 9, no. 5, doi:doi:10.1016/j.ccr.2006.03.030, pages 391 - 403, XP002550739 DOI: http://dx.doi.org/10.1016/j.ccr.2006.03.030
	- WAKIMOTO HMOHAPATRA GKANAI R et al., "Maintenance of primary tumor phenotype and genotype in glioblastoma stem cells", Neuro Oncol, (20120000), vol. 14, no. 2, pages 132 - 44
	- SHAH K, "Mesenchymal stem cells engineered for cancer therapy", Adv Drug Deliv Rev, (20120000), vol. 64, no. 8, doi:doi:10.1016/j.addr.2011.06.010, pages 739 - 48, XP028916800 DOI: http://dx.doi.org/10.1016/j.addr.2011.06.010
	- SOMOZA RARUBIO FJ, "Cell therapy using induced pluripotent stem cells or somatic stem cells: this is the question", Curr Stem Cell Res Ther, (20120000), vol. 7, no. 3, doi:doi:10.2174/157488812799859865, pages 191 - 6, XP008164521 DOI: http://dx.doi.org/10.2174/157488812799859865
	- MAHER EAMIETZ JARTEAGA CLDEPINHO RAMOHLA S, "Brain metastasis: opportunities in basic and translational research", Cancer research, (20090000), vol. 69, no. 15, pages 6015 - 6020
	- FIDLER IJSCHACKERT GZHANG RDRADINSKY RFUJIMAKI T, "The biology of melanoma brain metastasis", Cancer metastasis reviews, (19990000), vol. 18, no. 3, pages 387 - 400
	- SAMPSON JHCARTER JH, JR.FRIEDMAN AHSEIGLER HF, "Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma", Journal of neurosurgery, (19980000), vol. 88, no. 1, pages 11 - 20
	- KOHLER BA et al., "Annual report to the nation on the status of cancer, 1975-2007, featuring tumors of the brain and other nervous system", Journal of the National Cancer Institute, vol. 103, no. 9, pages 714 - 736
	- CHAMBERLAIN MC, "Brain metastases: a medical neuro-oncology perspective", Expert review of neurotherapeutics, vol. 10, no. 4, pages 563 - 573
	- BYRNE TNCASCINO TLPOSNER JB, "Brain metastasis from melanoma", Journal of neuro-oncology, (19830000), vol. 1, no. 4, pages 313 - 317
	- BINDAL RKSAWAYA RLEAVENS MELEE JJ, "Surgical treatment of multiple brain metastases", Journal of neurosurgery, (19930000), vol. 79, no. 2, pages 210 - 216
	- EIGENTLER TK et al., "Number of metastases, serum lactate dehydrogenase level, and type of treatment are prognostic factors in patients with brain metastases of malignant melanoma", Cancer, vol. 117, no. 8, pages 1697 - 1703
	- ZAKRZEWSKI J et al., "Clinical variables and primary tumor characteristics predictive of the development of melanoma brain metastases and post-brain metastases survival", Cancer, vol. 117, no. 8, pages 1711 - 1720
	- LIU TCGALANIS EKIRN D, "Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress", Nature clinical practice. Oncology, (20070000), vol. 4, no. 2, doi:doi:10.1038/ncponc0736, pages 101 - 117, XP009100877 DOI: http://dx.doi.org/10.1038/ncponc0736
	- RUSSELL SJPENG KWBELL JC, "Oncolytic virotherapy", Nature biotechnology, (20120000), vol. 30, no. 7, doi:doi:10.1038/nbt.2287, pages 658 - 670, XP055164204 DOI: http://dx.doi.org/10.1038/nbt.2287
	- MACKIE RMSTEWART BBROWN SM, "Intralesional injection of herpes simplex virus 1716 in metastatic melanoma", Lancet, (20010000), vol. 357, no. 9255, doi:doi:10.1016/S0140-6736(00)04048-4, pages 525 - 526, XP004800438 DOI: http://dx.doi.org/10.1016/S0140-6736(00)04048-4
	- SIVENDRAN SPAN MKAUFMAN HLSAENGER Y, "Herpes simplex virus oncolytic vaccine therapy in melanoma", Expert opinion on biological therapy, (20100000), vol. 10, no. 7, pages 1145 - 1153
	- SHAH K, "Mesenchymal stem cells engineered for cancer therapy", Advanced drug delivery reviews, (20120000), vol. 64, no. 8, doi:doi:10.1016/j.addr.2011.06.010, pages 739 - 748, XP028916800 DOI: http://dx.doi.org/10.1016/j.addr.2011.06.010
	- DUEBGEN M et al., "Stem cells loaded with multimechanistic oncolytic herpes simplex virus variants for brain tumor therapy", Journal of the National Cancer Institute, (20140000), vol. 106, no. 6

The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.

Legal notice
Terms of use
24.2.25; 35p